Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Since 2009 there is a new dexamethasone intravitreal implant (DII) to treat macular oedema following vascular obstruction and uveitis. The applicator system consists of a sterile, single-use instrument via 22-gauge needle and was designed to create a self-sealing wound.1 In the 12 months safety and efficacy study,2 including 1256 patients, no adverse events related to the sclerotomy wound were found.
The aim of this study is to describe the scleral wound closure using anterior segment spectral domain optical coherence tomography (AS-OCT) in 27 eyes of 23 patients treated with DII.
We designed a prospective observational study with 27 eyes of 23 consecutive patients treated with DII due to macular oedema. We excluded eyes with known allergies to the studied medication and other coexisting ocular disorders such as conjunctival or scleral scarring, aphakia, active ocular infection, glaucoma and intraocular pressure (IOP) >23 mm Hg.
All surgeries were performed under topical anaesthesia by two experienced vitreoretinal surgeons in accordance …
Contributors All the authors contributed to the conception and design, analysis and interpretation of data, drafting the article and ﬁnal approval of the version to be published.
Competing interests None.
Ethics approval Ethics committee from Araba University Hospital.
Provenance and peer review Not commissioned; externally peer reviewed.